. Author manuscript; available in PMC: 2021 Dec 27.

Published in final edited form as: J Clin Psychiatry. 2021 Dec 21;83(1):20m13763. doi: 10.4088/JCP.20m13763

Table 2.

Rates per 1,000 Veteran smokers and trends of incident varenicline and comparison nicotine replacement therapy among Veteran smokers overall

	Varenicline		Nicotine Replacement Therapy
	Coef. (SE)	95% CI	Coef. (SE)	95% CI
Pre-Warning Period
Rate of use at peak (October 2007)	6.23 (0.22)	5.81 to 6.66	10.74 (0.51)	9.74 to 11.74
Slope during pre-warning period	−0.27 (0.12)	−0.51 to −0.03^**	−0.48 (0.28)	−1.03 to 0.07
FDA Advisory Warning (February 2008)
Rate of use at start of warning period 1	3.36 (0.14)	3.09 to 3.63	9.02 (0.32)	8.39 ot 9.65
Slope change during warning period 1	0.11 (0.12)	−0.13 to 0.35	0.71 (0.28)	0.15 to 1.26^*
FDA Boxed Warning (July 2009)
Rate of use at start of warning period 2	1.00 (0.08)	0.85 to 1.16	10.49 (0.20)	10.10 to 10.89
Slope change during warning period 2	0.16 (0.02)	0.12 to 0.20^***	−0.26 (0.03)	−0.34 to −0.16^***
Removal of the Boxed Warning (December 2016)
Rate of use at start of post-warning period	1.09 (0.12)	0.85 to 1.32	9.03 (0.31)	8.42 to 9.64
Slope change during post-warning period	0.01 (0.01)	0 to 0.02	−0.06 (0.02)	−0.09 to −0.03^***
Rate of use at end of post-warning period	1.3 (0.12)	1.07 to 1.54	5.68 (0.31)	5.08 to 6.29

CI, confidence interval; Coef., coefficient; SE, standard error.

<0.05

^**

<0.01

^***

<0.001.